CSIMarket
 


Mallinckrodt Plc  (MNKKQ)
Other Ticker:  
 

Mallinckrodt Plc's Total Debt to Equity

MNKKQ's quarterly Total Debt to Equity and Total Debt, Equity growth


Due to net new borrowings of 0.04%, Total Debt to Equity fell to 7.13, a new company high.

Within Major Pharmaceutical Preparations industry in the first quarter 2022, 211 other companies have achieved lower Total Debt to Equity than Mallinckrodt Plc in the I Quarter 2022. While Total Debt to Equity total ranking has deteriorated compared to the forth quarter 2021 from 2425 to 3568 .

Explain Debt to Equity Ratio?
What is the structure of MNKKQ´s Total Debt?
How valuable is the MNKKQ´s Equity?


MNKKQ Total Debt to Equity (Apr 01 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 24 2021)
III. Quarter
(Jun 25 2021)
II. Quarter
(Mar 26 2021)
I. Quarter
Y / Y Equity Change -77.81 % -69.25 % -55.96 % -19.96 % -53.64 %
Y / Y Total Debt Change -18.35 % -61.29 % -73.52 % -67.52 % -68.33 %
Total Debt to Equity MRQ 7.13 4.43 2.7 2.19 1.94
MNKKQ's Total Ranking # 3568 # 2425 # 2904 # 2718 # 2554
Seq. Equity Change -37.78 % -38.96 % -33.84 % -11.71 % -13.77 %
Seq. Total Debt Change 0.04 % 0.06 % -18.49 % 0.08 % -52.57 %



Total Debt to Equity first quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 212
Healthcare Sector # 524
Overall Market # 3568


Total Debt to Equity Statistics
High Average Low
7.13 1.93 0.7
(Apr 01 2022)   (Dec 27 2013)




Financial Statements
Mallinckrodt Plc's Equity $ 195 Millions Visit MNKKQ's Balance sheet
Mallinckrodt Plc's Total Debt $ 1,390 Millions Visit MNKKQ's Balance sheet
Source of MNKKQ's Sales Visit MNKKQ's Sales by Geography


Cumulative Mallinckrodt Plc's Total Debt to Equity

MNKKQ's Total Debt to Equity for the trailling 12 Months

MNKKQ Total Debt to Equity

(Apr 01 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 24 2021)
III. Quarter
(Jun 25 2021)
II. Quarter
(Mar 26 2021)
I. Quarter
Y / Y Equity TTM Growth -77.81 % -69.25 % -55.96 % -19.96 % -53.64 %
Y / Y Total Debt TTM Growth -18.35 % -61.29 % -73.52 % -67.52 % -68.33 %
Total Debt to Equity TTM 3.26 2.49 2.63 3.19 3.91
Total Ranking TTM # 3605 # 3440 # 3078 # 3257 # 3474
Seq. Equity TTM Growth -37.78 % -38.96 % -33.84 % -11.71 % -13.77 %
Seq. Total Debt TTM Growth 0.04 % 0.06 % -18.49 % 0.08 % -52.57 %


On the trailing twelve months basis Due to the net new borrowings of 0.04% during the trailing twelve months finishing in the I Quarter 2022, cumulativeTotal Debt to Equity improved to 3.26, above the Mallinckrodt Plc's average Total Debt to Equity.
Total Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 63, during the past 12 months, other companies have achieved lower Total Debt to Equity than Mallinckrodt Plc. While Total Debt to Equity total ranking has deteriorated during the twelve months ending in the I Quarter 2022, compared to the prior period, from 992 to 455.

Explain Debt to Equity Ratio?
What is the structure of MNKKQ´s Total Debt?
How valuable is the MNKKQ´s Equity?

TTM Total Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 64
Healthcare Sector # 139
Within the Market # 3568


trailing twelve months Total Debt to Equity Statistics
High Average Low
3.91 1.48 0
(Mar 26 2021)   (June 30. 2016)




Companies with similar Total Debt to Equity in the quarter ending Apr 01 2022, within Major Pharmaceutical Preparations Industry Total Debt to EquityApr 01 2022 MRQ Total DebtApr 01 2022 MRQ Equity
Epizyme Inc.  19.48 $ 216.670  Millions$ 11.121  Millions
Revance Therapeutics Inc   14.80 $ 377.951  Millions$ 25.541  Millions
Puma Biotechnology Inc   13.63 $ 97.381  Millions$ 7.145  Millions
Ensysce Biosciences Inc   7.68 $ 8.531  Millions$ 1.111  Millions
Harrow Inc   7.38 $ 71.847  Millions$ 9.736  Millions
Clene Inc   7.29 $ 14.712  Millions$ 2.017  Millions
Mallinckrodt Plc  7.13 $ 1,389.500  Millions$ 195.000  Millions
Mallinckrodt Plc  7.13 $ 1,389.500  Millions$ 195.000  Millions
Amneal Pharmaceuticals Inc   6.64 $ 2,703.184  Millions$ 407.407  Millions
Insmed Inc  6.53 $ 783.156  Millions$ 119.880  Millions
Heron Therapeutics Inc   6.22 $ 149.132  Millions$ 23.958  Millions
Athenex Inc   6.10 $ 126.911  Millions$ 20.799  Millions
Avalo Therapeutics Inc   5.23 $ 33.183  Millions$ 6.343  Millions
Abbvie inc   4.50 $ 73,474.000  Millions$ 16,314.000  Millions
Agile Therapeutics Inc  4.47 $ 12.252  Millions$ 2.743  Millions
Rigel Pharmaceuticals Inc  4.39 $ 29.847  Millions$ 6.798  Millions
Global Blood Therapeutics Inc.  4.34 $ 581.189  Millions$ 134.002  Millions
Collegium Pharmaceutical Inc   3.92 $ 768.579  Millions$ 196.076  Millions
Jaguar Health inc   3.91 $ 31.673  Millions$ 8.109  Millions
Akebia Therapeutics Inc   3.75 $ 97.848  Millions$ 26.116  Millions
Gelesis Holdings Inc   3.58 $ 35.959  Millions$ 10.037  Millions
Aslan Pharmaceuticals Limited  3.55 $ 29.656  Millions$ 8.365  Millions
Axsome Therapeutics Inc   3.36 $ 49.313  Millions$ 14.698  Millions
Novan Inc   2.81 $ 16.500  Millions$ 5.882  Millions
Precigen Inc   2.73 $ 201.467  Millions$ 73.836  Millions
Evoke Pharma Inc   2.59 $ 5.000  Millions$ 1.934  Millions
Avadel Pharmaceuticals Plc  2.58 $ 142.709  Millions$ 55.232  Millions
Phathom Pharmaceuticals Inc   2.39 $ 91.037  Millions$ 38.035  Millions
Societal Cdmo Inc   2.38 $ 93.240  Millions$ 39.162  Millions
Teva Pharmaceutical Industries Limited  2.23 $ 22,917.000  Millions$ 10,260.000  Millions

Date modified: 2023-08-20T01:27:18+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com